Lithium cocrystal - Alzamend Neuro
Alternative Names: AL-001-Alzamend Neuro; LiProSal; LiProSalTM; Lithium salicylate/L-proline cocrystalLatest Information Update: 20 Jun 2025
At a glance
- Originator University of South Florida
- Developer Alzamend Neuro
- Class Alkali metals; Antidementias; Antidepressants; Antimanics; Antipsychotics; Light metals; Small molecules
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Bipolar disorders; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 16 Jun 2025 Alzamend Neuro plans a phase IIa clinical trial for Alzheimer’s disease in the fourth quarter of 2025
- 23 May 2025 Alzamend Neuro completes phase-II clinical trials in Alzheimer's disease (In volunteers) in USA (PO)
- 19 May 2025 Alzamend Neuro initiates phase II clinical trials in Alzheimer's disease (In volunteers) in USA (PO)